JAK Inhibitor News and Research

RSS

Study reveals immune dysregulation in Down syndrome and potential therapeutic strategy

People with Down syndrome, the condition caused by an extra copy of chromosome 21, or trisomy 21, display chronic dysregulation of their immune system, which can contribute to high rates of autoimmune conditions and severe complications from respiratory infections.

17 Jul 2023

Patients with myelofibrosis show improvement in disease-related symptoms when treated with momelotinib

Patients with myelofibrosis had clinically significant improvement in disease-related symptoms, including anemia and spleen enlargement, when treated with the targeted therapy momelotinib, according to results from the international Phase III MOMENTUM trial led by researchers at The University of Texas MD Anderson Cancer Center.

29 Jan 2023

CHLA launches first clinical trial for Down syndrome regression disorder with $5.3 million NIH grant

Children's Hospital Los Angeles has launched the first clinical trial for Down syndrome regression disorder (DSRD), a rare and debilitating condition that affects adolescents and young adults with Down syndrome.

23 Jan 2023

Study reviews mechanistic data on new methods of allergy prevention and treatment

In a recent article published in Science Translational Medicine, researchers reviewed the cause and the underlying pathophysiology of allergic diseases.

23 Jan 2023

Does skin inflammation exacerbate COVID-19?

In a new study, researchers discussed inflammation during infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

18 Oct 2022

Antibody drugs are not recommended for patients with covid-19, say WHO experts

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with covid-19, says a WHO Guideline Development Group of international experts in The BMJ today.

16 Sep 2022

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

With this approval, RINVOQ® is the first and only Janus Kinase inhibitor approved to treat patients across the spectrum of axial spondyloarthritis (nr-axSpA and ankylosing spondylitis) in the EU.

From AbbVie 29 Jul 2022

Oral pill taken once a day improves outcomes of patients with myelofibrosis

Momelotinib, an oral pill taken once a day, significantly improved outcomes of patients treated for myelofibrosis (MF), a rare but fatal bone marrow cancer, researchers reported June 7.

7 Jun 2022

Cycling JAK inhibitors can be effective for treating people with difficult-to-treat rheumatoid arthritis

New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows that people with difficult-to-treat rheumatoid arthritis who do not have success with one Janus kinase inhibitor (JAK inhibitor) can achieve success either cycling to other JAKi medications or switching to a biologic drug.

2 Nov 2021

Study shows impaired SARS-CoV-2 mRNA vaccine antibody response in individuals with chronic conditions

A recent study in Colorado used real-world data to evaluate if individuals with chronic conditions have reduced antibody response to COVID-19 mRNA vaccines. The study investigated whether some medical conditions may impact antibody response to the mRNA vaccines.

9 Aug 2021

Autoimmune condition biomarkers promote SARS-CoV-2 viral entry, study finds

Researchers have reported that the autoimmune PTPN2 risk variant rs1893217 promotes the expression of the SARS-CoV-2 receptor, ACE2, and thus promotes cellular entry, which is mediated by SARS-CoV-2 spike S protein.

16 Dec 2020

Novel super-activating macrophage receptor could explain hyper-inflammation in severe COVID-19

Immunity is a curious thing. While essential in protecting the body against invading pathogens and foreign antigens, it can also turn against the body and trigger destructive immunological processes. A new study published on the preprint server bioRxiv* in November 2020 reports on the role played by hyperactive macrophages in a range of acute and chronic hyper-inflammatory conditions.

10 Nov 2020

Study shows tofacitinib drug can repair permeability defects in the intestine

A team of researchers led by biomedical scientist Declan F. McCole at the University of California, Riverside, has found that the drug tofacitinib, also called Xeljanz and approved by the FDA to treat rheumatoid arthritis and ulcerative colitis, can repair permeability defects in the intestine.

30 Sep 2020

Researchers discover treatment for severe auto inflammatory syndrome

Researchers from the Icahn School of Medicine used a novel genetic sequencing technology to identify the genetic cause of--and a treatment for--a previously unknown severe auto inflam-matory syndrome affecting an 18-year-old girl since infancy.

4 Aug 2020

Insilico Medicine, Arctoris announce technology partnership to discover new COVID-19 drugs

Insilico Medicine, a biotechnology company developing an end-to-end drug discovery pipeline utilizing next-generation artificial intelligence, today announced a technology partnership with Arctoris, the world's first fully automated drug discovery platform, offering remotely accessible, pre-optimized and fully validated R&D processes for its partners and clients globally.

9 Jul 2020

Could JAK blockers help treat COVID-19?

A new study published in the journal Science Immunology in May 2020 reports that compounds that safely inhibit the JAK protein could be useful in treating COVID-19.

12 May 2020

Yale researchers use arthritis medication to treat patient with disfiguring sarcoidosis

An all-Yale team of researchers successfully treated a patient with disfiguring sarcoidosis, a chronic disease that can affect multiple organs, with a drug approved for rheumatoid arthritis.

26 Dec 2018

Study adds more evidence to underlying autoimmune mechanisms in type 1 diabetes

Immune reactions are usually a good thing-;the body's way of eliminating harmful bacteria and other pathogens. But people also rely on molecular "brakes," or checkpoints, to keep immune systems from attacking their own cells and organs and causing so-called autoimmune disease.

29 Aug 2018

New treatment option could provide effective therapy for patients with dermatologic conditions

Alopecia areata, atopic dermatitis and vitiligo are highly visible dermatologic conditions that can have a negative effect on patients' quality of life and overall health. An emerging treatment option, however, could provide effective therapy for patients with these conditions.

3 Mar 2017

JAK inhibitors show promise in restoring hair growth in patients with alopecia areata

Seventy-five percent of patients with moderate to severe alopecia areata--an autoimmune disease that causes patchy, and less frequently, total hair loss--had significant hair regrowth after treatment with ruxolitinib, reported researchers from Columbia University Medical Center. By the end of their treatment, average hair regrowth was 92 percent.

5 Oct 2016